Evaluating Vonoprazan and Tegoprazan for Gastroesophageal Reflux Disease Treatment in Chinese Healthcare: An EVIDEM Framework Analysis

Abstract Background In Chinese healthcare settings, decisions regarding drug selection are predominantly guided by the Pharmacy & Therapeutics Committee (PTC). This study focuses on two recently introduced potassium-competitive acid blockers in China, vonoprazan (VPZ) and tegoprazan (TPZ). The objective was to assess these drugs using the Evidence and Value: Impact on DEcisionMaking (EVIDEM) framework. Methods This study utilized the 10th edition of EVIDEM, comprising a core model with five domains and 13 criteria. It involved two independent expert panels. The PTC expert panel was tasked with five responsibilities: assigning weights using a 5-point scale, defining scoring indicators, examining the evidence matrix, scoring, and decision-making. The evidence matrix expert panel had three duties: conducting a systematic literature review, creating the evidence matrix, and evaluating the value contributions of VPZ and TPZ. Results The analysis estimated the value contributions of VPZ and TPZ at 0.59 and 0.54, respectively. The 'economic consequences of intervention' domain exhibited the most significant variation in value contribution between the two drugs, followed by 'comparative outcomes of intervention' and 'type of benefit of intervention'. Conclusion Utilizing the EVIDEM framework, VPZ's value contribution appears marginally superior to that of TPZ. The EVIDEM framework shows promise for application in Chinese medical institutions.